Stocklytics Platform
Asset logo for symbol TXG
10X Genomics
Asset logo for symbol TXG


Key Stats
Prev. Close$17.32
Next Earnings Date-
Dividend Yield %-
PE Ratio-
Day Range17.30
52 Week Range15.28
Payout Ratio-
Industry average yield3.04%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up1.59%
US Marketarrow_drop_up1.11%
TXG / Market
TXG exceeded the US Market which returned 1.11% over the last twenty four hours.
TXG / Healthcare Sector
TXG exceeded the US Healthcare sector which returned 1.59% over the last twenty four hours.

10X Genomics (TXG) Statistics

10X Genomics Inc (TXG) is a biotechnology company based in Pleasanton, California. It specializes in developing and manufacturing integrated systems for gene sequencing, gene expression profiling, and single-cell analysis. The company's products enable researchers to analyze biological systems at a high resolution and gain insights into disease mechanisms and therapeutic targets.

When it comes to stock statistics, investors look at various metrics to assess the company's performance. For 10X Genomics Inc (TXG), valuation metrics such as price-to-earnings ratio, price-to-sales ratio, and price-to-book ratio provide an indication of the company's relative value compared to its earnings, sales, and book value. These metrics help investors determine whether the stock is undervalued or overvalued.

add 10X Genomics  to watchlist

Keep an eye on 10X Genomics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has 10X Genomics (TXG) stock's performance compared to its sector and the market over the past year?

Over the past year, 10X Genomics (TXG) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 27.95%, 10X Genomics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 52.74%, it has fallen short of the market average. This comparison highlights 10X Genomics 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of 10X Genomics (TXG) stock?

The PE ratio for 10X Genomics (TXG) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of 10X Genomics (TXG) stock?

The Earnings Per Share (EPS) for 10X Genomics (TXG), calculated on a diluted basis, is -$2.24. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of 10X Genomics (TXG) stock?

The operating margin for 10X Genomics (TXG) is -42.12%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of 10X Genomics (TXG) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of 10X Genomics (TXG) is -$164.14M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does 10X Genomics (TXG) have?

10X Genomics (TXG) has a total debt of $92.18M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$263.6M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level